Here’s a roundup of companies announcing new distribution deals.
- LabCorp expands XDx blood diagnostics deal
XDx Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, entered into a multi-year agreement with Laboratory Corp. of America Holdings (NYSE:LH) to provide heart transplant patients eligible for XDx’s AlloMap test with the convenience of having their blood drawn at participating LabCorp sites across the United States. Under the terms of the agreement, LabCorp will be XDx’s preferred third-party non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America. This expanded agreement follows a successful one-year pilot between the companies at select LabCorp blood draw sites. The XDx reference lab will also continue to perform the proprietary AlloMap test.
- Health Robotics re-enters Italian market
Health Robotics decided to re-start sales and service operations in Italy, after a three-year absence in connection with a prior agreement with Gruppo Loccioni. With over 60 hospital customers under contract carried forward from the company’s 2006-2007 presence in the Italian market, Health Robotics is on the brink to replicate its worldwide success within its home country of Italy. The company’s All-Digital solutions, including Oncology Care, will continued to be showcased at its pre-2008 installations: Campus Biomedico University Hospital, La Maddalena Cancer Center, Ospedale di Treviso, Gruppo Auxologico in Milan, and Bolzano General Hospital.
- Innocutis Medical inks exclusive marketing agreement for INSORB absorbable skin stapler
Innocutis Medical, a dermatology company focused on novel surgical devices and specialty pharmaceuticals, entered an exclusive marketing agreement with Incisive Surgical Inc. for the sales and marketing rights within the dermatology market for the patented INSORB Absorbable Skin Stapler, a revolutionary new modality for skin closure. The INSORB Stapler uses bioabsorbable staples that are placed under the skin and dissolve in the body within a matter of months. The staples, which are comprised of the same material as the leading bioabsorbable sutures, break down naturally, meaning there is no need for post-operative removal. With over a half a million surgical cases performed within the hospital market, INSORB has developed a solid and proven track record. INSORB’s introduction to the dermatology community will allow for increased surgical efficiency, improved cosmetic outcomes, and reduced risk of infection over traditional suture techniques.
- Life Technologies partners with Partek for data analysis
Partek Inc. a global leader in bioinformatics software, signed of a distribution agreement with Life Technologies Corp. (NSDQ:LIFE), a provider of next-generation DNA sequencing technology. The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies’ next-generation sequencing (NGS) devices.
- Cord Blood America signs second supply deal with international tissue bank for placenta and umbilical cord collection services
Cord Blood America Inc. (OTC:CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, signed a supply agreement with a premier national and international cell and tissue bank to provide placenta, umbilical cord blood and whole umbilical cord collection services for research purposes.